MaxCyte sees FY25 core business revenue up 8%-15%
The company said, “Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related ...
Hosted on MSN1mon
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Raises Q4 Guidance Driven by SPL Revenue MaxCyte sells electroporation tools and Strategic Platform License (SPLs). The net present value (NPV) of an SPL is $85 million, according to MaxCyte.
Yahoo Finance10d
MaxCyte, Inc. (MXCT)
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...
The Business Journals1mon
Rockville biotech MaxCyte snaps up Boston-area diagnostics startup SeQure Dx
The deal came together about a year after a big leadership change. MaxCyte Inc. has made its first acquisition in its more than quarter-century of operation, about a year after its current CEO ...
ETF Daily News6d
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MaxCyte, Inc, a life sciences company, discovers, develops, and ...
Nasdaq1mon
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...